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Abstract
Speciﬁc ﬂavonoid-rich foods/beverages are reported to exert positive effects on vascular function; however, data relating to effects in the
postprandial state are limited. The present study investigated the postprandial, time-dependent (0–7 h) impact of citrus ﬂavanone intake on
vascular function. An acute, randomised, controlled, double-masked, cross-over intervention study was conducted by including middle-aged
healthy men (30–65 years, n 28) to assess the impact of ﬂavanone intake (orange juice: 128·9mg; ﬂavanone-rich orange juice: 272·1mg;
homogenised whole orange: 452·8mg; isoenergetic control: 0mg ﬂavanones) on postprandial (double meal delivering a total of 81 g of fat)
endothelial function. Endothelial function was assessed by ﬂow-mediated dilatation (FMD) of the brachial artery at 0, 2, 5 and 7 h.
Plasma levels of naringenin/hesperetin metabolites (sulphates and glucuronides) and nitric oxide species were also measured. All ﬂavanone
interventions were effective at attenuating transient impairments in FMD induced by the double meal (7 h post intake; P< 0·05), but no dose–
response effects were observed. The effects on FMD coincided with the peak of naringenin/hesperetin metabolites in circulation (7 h) and
sustained levels of plasma nitrite. In summary, citrus ﬂavanones are effective at counteracting the negative impact of a sequential double meal
on human vascular function, potentially through the actions of ﬂavanone metabolites on nitric oxide.
Key words: Citrus ﬂavanones: Endothelial function: High-fat meals: Nitric oxide: Postprandial state
A transient impairment in vascular function is known to occur in
the postprandial or fed state(1–4) and is widely believed to impact
on endothelial dysfunction and lifetime CVD risk(5–8). In particular,
endothelial function has been shown to be transiently impaired
(2–8h) following ingestion of moderate- to high-fat meals (36–80g
of fat)(9–13), potentially driven by hyperglycaemia and hyper-
triglyceridaemia, which occurs during the postprandial state(1,14,15).
Observational data have highlighted that the consumption of diets
rich in ﬂavonoids might lead to an improved cardiovascular
prognosis(16–20). Indeed, ﬂavonoid-rich foods and beverages are
well reported to improve endothelial function acutely in humans
both at(21–24) short term(25–27) and long term(28–31). However, most
of the acute interventions were undertaken with volunteers in
the fasted state, which is considered less representative of the
free-living state, whereas data relating to ﬂavonoid potential to
ameliorate acutely postprandial endothelial impairments are more
scarce(32–34).
Although the precise mechanisms by which absorbed
ﬂavonoids and their circulating metabolites mediate beneﬁcial
vascular effects remain unclear, there is evidence to suggest
that the modulation of circulating nitric oxide (NO) levels might
be involved(22–24,35–38). Notably, ﬂavanol-rich cocoa has been
consistently shown to improve endothelium-dependent vasodila-
tion in healthy individuals(24,27,31,39,40), smokers(23,26), patients with
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coronary artery disease(41), hypertension(42) or diabetes(43).
In particular, acute vascular improvements have been shown
to coincide with the appearance of ﬂavanol metabolites in
the circulation and with peak plasma NO levels(23,24,26,42).
Furthermore, ﬂavanol-induced improvements in vascular function
are inhibited following co-administration of an endothelial nitric
oxide synthase (eNOS) inhibitor, suggesting a cause-and-effect
relationship between ﬂavonoid intake, plasma NO levels and
vascular function(23,24). Although less studied, ﬂavanones from
citrus fruits have also been shown to exert beneﬁcial effects on
human vascular function(28,44). In particular, chronic interventions
with orange juice, or the pure ﬂavanone hesperidin, resulted in a
decrease in blood pressure in overweight volunteers and acute
(6 h) improvements in micro-vascular reactivity(45). Short-term
intake of pure hesperidin also resulted in signiﬁcant improvements
in endothelial function (as measured by brachial artery
ﬂow-mediated dilation (FMD)) in volunteers with the metabolic
syndrome(46).
In the present study, we assessed the impact of an acute
intervention with increasing doses of orange ﬂavanones
(sourced from differently processed orange beverages) on
human vascular function in the postprandial state. A sequential
double meal (breakfast and lunch, delivering a total of 81 g of
fat) was used to simulate the fed state and investigate the
postprandial time-dependent effects of ﬂavanone intake on
endothelial function as measured by brachial artery FMD.
Methods
Ethics
The clinical trial was registered at clinicaltrials.gov (NCT01963416)
and conducted according to the Declaration of Helsinki following
Good Clinical Practice. It was approved for conduct by the
University of Reading’s Research Ethical Committee (ethics
reference no. 12/06). All volunteers signed an informed consent
form before commencing the study.
Intervention study volunteers
Volunteers were recruited from the University of Reading and
surrounding areas using the Hugh Sinclair Unit volunteers’
database, poster advertisements within the university and local
community via local websites (April–December 2012). In total,
ﬁfty-nine, healthy, male volunteers, aged 30–65 years, were
assessed for screening and were selected according to the
following inclusion criteria: (1) fasting lipids in the upper half of
the normal range (TAG 0·8–3·2mmol/l and total cholesterol
6·0–8·0mmol/l) or BMI 25–32kg/m2; (2) non-smoker;
(3) non-diabetic (diagnosed or fasting glucose>7mmol/l) with no
endocrine disorders; (4) Hb and liver enzyme levels within the
normal range; (5) not having suffered a myocardial infarction/
stroke in the past 12 months; (6) not suffering from renal or bowel
diseases or having a history of cholestatic liver or pancreatitis;
(7) not on drug treatment for hyperlipidaemia, hypertension,
inﬂammation or hyper-coagulation; (8) not taking any ﬁsh oil,
fatty acid or vitamin and mineral supplements; (9) no history
of alcohol misuse; (10) not planning weight loss or on a
weight-reducing regimen; (11) not taken antibiotics during the
6 months before the study; and (12) not being able to consume
the study meals. Those selected for the study were instructed not
to alter their usual dietary or ﬂuid intakes. Volunteers were asked
to refrain from the following for 24h before and during the study:
(1) consumption of polyphenol-rich foods including fruits
(including citrus fruits), vegetables, cocoa, chocolate, coffee, tea,
fruit juices and wine; (2) consumption of foods rich in nitrates,
including beetroot, spinach, lettuce, rocket, celery, parsley and
cabbage (deﬁned as containing >50mg nitrates/100 g fresh
weight(47); (3) performing rigorous exercises; and (4) consuming
any alcoholic beverage. Volunteers were further asked to fast for
12h before each study visit, and during that period they were to
only consume the low-nitrate water provided. The same standard
meal, low in polyphenols and nitrates, was also provided for
dinner for the day before each visit. Written informed consent was
obtained from all eligible volunteers before their participation in
the study.
Study design
The study design was an acute, randomised, placebo-controlled,
double-masked, postprandial, cross-over study (Fig. 1). After the
initial screening visit to assess the eligibility of volunteers for
participation, volunteers were enrolled into the study (by
researchers C. R. and H. D.) and visited the Hugh Sinclair Unit at
the University of Reading on four separate occasions separated
by a 2-week period (June–December 2012). Volunteers were
asked to consume either a (a) control drink (C), (b) orange juice
beverage (OJ), (c) ﬂavanone-rich orange juice (FROJ) or
(d) whole orange beverage (WO), together with a high-fat
breakfast (at baseline, t=0h), followed by a medium-fat lunch
(t=5·5h). H. D. assigned participants to the three-digit coded
drink interventions for their four visits according to a random
allocation sequence generated by a third party. Details on
ﬂavonoid composition of the interventions, as well as micronutrient
and macronutrient compositions, can be found on Table 1.
Compliance to a 24-h low-polyphenol intake period and 12h of
fasting was monitored using a 24-h dietary recall conducted
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Fig. 1. Consolidated Standards of Reporting Trials flow diagram for the
postprandial study.
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during each study visit. On each visit day, volunteers rested for
30min in a quiet, temperature-controlled room before they were
cannulated by a qualiﬁed research nurse; blood samples were
collected in the fasted state (0h) and at 2, 5, 7 and 24h after
consumption of each intervention drink. FMD of the brachial
artery was the primary outcome and it was measured at 0, 2, 5
and 7h after consumption. Secondary outcomes of the study
included systolic and diastolic blood pressures (0, 2, 5, 7h),
plasma ﬂavanone levels (0, 2, 5, 7, 24h) and NO plasma levels
(0, 2, 5, 7h). After baseline measurements were obtained, the
high-fat breakfast (Table 2) was consumed with one of the clinical
products (C, OJ, FROJ, WO). Volunteers were asked to consume
the intervention drink and the high-fat meal within 10–15min. At
5·5h from baseline, a medium-fat lunch was provided (Table 2).
The last measurement of the day was performed at 7h, and
the volunteers were asked to return to the clinical unit the
following morning to provide a 24-h blood sample (fasted). From
7 to 24h, volunteers were asked to consume the free polyphenol
dinner provided by the research team and to continue on the
low-polyphenol diet, as well as refrain from exercise and
alcohol consumption. Blood samples for ﬂavonoid analysis
were collected in EDTA-containing tubes (Greiner Bio-One Ltd),
immediately centrifuged for 15min at 4°C (4000 g), and the plasma
samples were spiked with formic acid (1·5% of a 50% water
solution) and ascorbic acid (5% of a 10mM solution) and stored
at −80°C. Blood samples for NO analysis were collected in heparin-
containing tubes, immediately (within 3min of collection)
centrifuged for 15min at 4°C (4000 g), and plasma was rapidly
collected, aliquoted and stored at −80°C to reduce inactivation of
nitroso species.
Sequential double meal
The sequential double-meal protocol was based on the
department’s extensive experience on postprandial studies,
which have been collated into the Dietary Studies: Reading
Unilever Postprandial Trials (DISRUPT) database(48).
It consisted of two meals: (1) high-fat breakfast (51 g fat; 14 g
protein; 64 g carbohydrates; 3251 kJ (777 kcal)) administered
with the intervention drink and (2) medium-fat lunch (30 g fat;
15 g protein; 80 g carbohydrates; 2628 kJ (628 kcal)) (Table 2)
administered 5·5 h after the intervention drink. The high-fat
meal consisted of two butter croissants (47 g of fat) and 5 g of
butter (4 g of fat). The medium-fat meal consisted of two slices
of white bread (2 g of fat), 42 g of Philadelphia soft cheese
(13 g of fat), a small bag of salted crisps (9 g of fat) and two
shortbread biscuits (6 g of fat) (Table 2). The volunteers were
asked to consume meals within 10–15min.
Flavanone-containing interventions
The preparations of the intervention drinks were carried out
according to good manufacturing practice as described in hazard
analysis and critical control points (HACCP). The control (C) drink
was matched for sugars found in the orange beverages, and 0·67%
citric acid and orange ﬂavouring were added to enhance ﬂavour.
The levels of total β-carotenes present in the ﬂavanone treatments
were considered negligible (approximately 0·25mg; 2 relative
standard deviation of the measurement (2-RSD): 15%) with regard
to endothelial function effects, with a 15-mg dose (6 weeks
intervention, in combination with 150mg of vitamin C) resulting
in no signiﬁcant changes on endothelial biomarkers(49) (Table 1).
The levels of folate present (approximately 60μg; 2-RSD: 16%)
can also be considered insigniﬁcant with regard to its potential to
impact on endothelial function; folate has been shown to drive
small improvements in endothelial function only in long-term
interventions (1–4 months) with at least 5000–10000μg/d of folate,
but not with lower doses in the ranges of 400–800μg/d(50).
Table 1. Compositional analysis of orange flavanone beverages and
control beverage used in the acute postprandial study
(2 Relative standard deviation of the measurement (2-RSD))
Intervention drink (240ml)
Compounds 2-RSD (%) Control OJ FROJ WO
Hesperidin (mg) 5·0 – 107·30 220·46 352·80
Narirutin (mg) 5·0 0·08 15·41 34·54 76·58
Others (mg)* 0·02 6·17 17·14 23·33
Total flavonoids (mg) 0·10 128·88 272·14 452·71
Fructose (g) 4·0 6·38 6·63 6·12 6·89
Glucose (g) 4·0 5·36 5·36 5·10 5·87
Sucrose (g) 2·0 10·20 10·97 11·99 11·48
Total sugars (g) 21·93 22·95 23·21 24·23
Fibre (total) (g) 12·0 – 0·66 5·36 6·30
Ascorbic acid (mg) 8·0 – 105·57 80·17 123·01
Folate (μg) 16·0 – 54·06 65·28 64·77
Total β-carotenes (mg) 15·0 – 0·13 0·26 0·35
Control, sugar matched control; OJ, Tropicana pure premium orange juice without
pulp; FROJ, flavanone-rich orange juice: Tropicana pure premium orange juice with
added orange pomace; WO, juice made from lightly blended fresh whole orange.
* Includes diosmin, didymin, nobiletin, tangeretin, sinensetin, Me4-scutellarein.
Table 2. Macronutrient composition of double-meal protocol
Macronutrient breakdown
Foods Fat (g) Protein (g) Carbohydrates (g) Energy (kJ) Energy (kcal)
High-fat breakfast Butter croissant (2×) 47 14 64 3096 740
Butter (5 g) 4 N/A N/A 159 37
Total 51 14 64 3251 777
Medium-fat lunch 2 slices of sliced white bread (108 g) 2 8·5 50 992 237
Philadelphia soft cheese (42 g) 13 3·6 N/A 548 131
Crisps (25 g) 9 1·5 13 556 133
Shortbread biscuit (22 g) 6 1·4 16 531 127
Total 30 15 80 2628 628
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The OJ used for the intervention was a commercial 100%
pure orange juice (Tropicana Pure Premium). The FROJ used was
Tropicana Pure Premium with added orange pomace. Pomace is
the edible part of a whole orange that is leftover during the
production of Tropicana pure premium orange juice and subjected
to particle size reduction. Orange pomace is rich in ﬁbre (40:60 ratio
of soluble:insoluble) and contains small amounts of micronutrients
and a high proportion of the polyphenols found in whole orange.
The WO consisted of lightly blended whole table orange, without
the peel. Drinks displayed slightly different viscosities, but speciﬁc
measurements were not undertaken to assess this. All drinks were
stored in individual portions (255g/240ml) in aluminium canisters,
frozen at −20°C and labelled with a three-digit code to ensure
double-masking. Drinks were defrosted overnight in the fridge
(4°C) just before being used on each study day. Participants,
care-providers and all researchers assessing outcomes were blinded
until all the data were analysed. Quantiﬁcation of ﬂavanones
from orange beverages (OJ, FROJ and WO) was performed by
ultra-HPLC coupled with tandem MS (UHPLC-MS/MS). Sample
preparation was performed by diluting the juice sample with
dimethyl sulfoxide, the internal standard (IS) solution (10µg/ml
d4-dimethyl phthalate in 50% acetonitrile–water) and 50% acet-
onitrile–water, followed by vortexing and centrifugation (10min,
2500 rpm). The supernatant was ﬁltered before analysis in an
Agilent 1290 UHPLC (Agilent Technologies), with a Zorbax Eclipse
Plus C18 column (1·8µm, 2·1×100mm; linear gradient starting at
100% (A) containing 2% acetonitrile in water with 0·1% formic acid,
to 90% (B) containing acetonitrile with 0·1% formic acid, followed
by 100% B). MS detection was performed in electrospray ionisation
(ESI)-positive ion mode on an Agilent 6530A Q-ToF MS with
MassHunter Software for instrument control and data processing.
Calibration standards were prepared from analytical grade materials
purchased from Indoﬁne Chemical Chromadex or LKT Labora-
tories. The levels of ﬂavanones in the test products are presented in
Table 1. In brief, the total levels of ﬂavanones in (a) OJ was
128·88mg, (b) in FROJ 272·14mg and (c) in WO 452·80mg
(Table 1). The ﬂavanone hesperidin was the main ﬂavonoid present
in the intervention beverages, ranging from 107·30mg (OJ) to
352·80mg (WO).
Flow-mediated dilation
FMD of the brachial artery was the primary end point measure of
the study, and measurements were taken following standard
guidelines(51) using an ALT Ultrasound HDI5000 system (ATL
Ultrasound) in combination with a semi-automated computerised
analysis system (Brachial Analyzer; Medical Imaging Applications
LLC). In brief, after 15min of rest in the supine position in a
quiet air-conditioned room, the brachial artery was imaged
longitudinally at 2–10 cm proximal to the antecubital fossa. After
baseline images were recorded for 60 s, a blood pressure cuff
placed around the forearm was inﬂated to 220mmHg. After 5min
of occlusion, the pressure was rapidly released to allow reactive
hyperaemia, with image collection continuing for 5min after
release. A single researcher, who was blinded to the measurement
details, analysed all image ﬁles, and peak diameter was deﬁned as
the largest diameter obtained after the occlusion was released.
FMD response was calculated as relative diastolic diameter change
from baseline as compared with peak diastolic diameter. A total of
twenty-eight volunteers were analysed for their FMD response.
Data from eight volunteers were not analysed or were excluded
because of the following reasons: (i) measurement of FMD from
the non-dominant arm (rather than dominant) due to limitations
with blood collection (n 2); (ii) absence of FMD response (n 3);
and (iii) technical problems during recording of ultrasound FMD
measurements rendered non-analysable data (n 3).
Blood pressure
Systolic and diastolic blood pressures were measured using an
Omron MX2 automatic digital upper-arm blood pressure monitor
(Omron Healthcare UK Ltd). All measurements were taken
according to standard practice and by a qualiﬁed research nurse,
before and following each intervention period. Before starting
blood pressure measurements, the volunteers were seated or were
laying down quietly for at least 20min. Measurements were taken
in the right arm, before FMD procedure for each time point.
The subject’s right arm was allowed to rest on a pillow (on a side
table positioned at heart level) and was slightly ﬂexed with the
palm facing upward. Volunteers were asked to refrain from
speaking during blood pressure measurements. The measure-
ments were repeated three times, and blood pressure was con-
sidered as the average of these measurements.
Plasma ﬂavanone analysis
Blood samples were collected in EDTA-containing tubes and cen-
trifuged at 4°C for 10–15min at 4000 g. Formic acid (1·5% of a 50%
solution) and ascorbic acid (5% of a 10-mM solution
prepared fresh everyday) were added to the plasma samples to
preserve ﬂavanones before freezing at −80°C. A subset of twenty
volunteers was selected randomly for analysis of ﬂavanone
content. A high throughput analytical method using UHPLC-MS/MS
was developed and validated to measure simultaneously naringenin
and hesperetin in human plasma. Enzymatic hydrolysis and
methanol extraction were applied as described earlier(52) with
modiﬁcations to accommodate in situ monitoring of enzyme efﬁ-
ciency and automated sample preparation using a Hamilton
Microlab Star liquid handling system (Hamilton). Plasma samples
(45 litres) were incubated after addition of β-glucuronidase type VII-
A (Sigma) and sulfatase type H-5 (Sigma) for 90 and 60min at 37°C,
respectively. To monitor enzyme activity, every individual sample
was spiked with a known concentration of phenolphthalein
glucuronide and potassium 4-nitrophenyl sulfate (Sigma) as
enzyme substrates in addition to caffeine-(trimethyl-d9) (Sigma)
as IS before incubation. The enzyme-hydrolysed samples were
subsequently extracted with methanol and centrifuged. The super-
natant (6 litres) was analysed using an Agilent 1290 UHPLC coupled
with an Agilent 6490 triple quadrupole MS (Agilent Technologies).
Naringenin and hesperetin were separated in a Waters BEH C18
(100×2·1mm, 1·7 micrometre particle size) at a ﬂow rate of 0·6ml/
min using 6·5-min gradient 99% solvent A (water containing 0·1%
formic acid) and 1% solvent B (acetonitrile containing 0·1% formic
acid) (initially; 70% solvent A at 0·5min; 55% solvent A at 2·5min;
2% solvent A at 3·0min; 2% solvent A at 4·0min; 99% solvent A
at 4·5min followed by post-equilibration for 2min). The MS was
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operated in ESI-positive ionisation mode and multiple reaction
monitoring (MRM) mode by monitoring quantiﬁer and qualiﬁer
ions for both naringenin and hesperetin. MRM transitions were
determined as 204·1/144·0 (m/z) corresponding to caffeine, as
495·1/319·1 (m/z) corresponding to phenolphthalein–glucuronide
and as 217·9/137·9 (m/z) corresponding to potassium
4-nitrophenyl sulphate as quantiﬁer ions. MRM transitions were
determined as 303·1/153·1 (m/z) corresponding to hesperetin and
273·1/147·1 (m/z) corresponding to naringenin as qualiﬁer ions.
Concentrations of hesperetin and naringenin were then calculated
on the basis of ratios of their integrated peak area for the quantiﬁer
ions to that of IS using two sets of eight-point calibration curves.
Accuracy of the analysis was monitored by systematic counter-
balancing between plasma samples and quality control samples
spiked with known concentrations of hesperetin and naringenin.
The method was validated for a linear calibration range of
0·0313–8·02µm for naringenin and 0·0282–7·22µm for hesperetin,
respectively. In addition, limits of detection for naringenin and
hesperetin were determined as 2 and 7nm, respectively.
Biochemical analysis
The blood samples collected in pre-chilled Li or heparin tubes
were spun (4000 g; 10–15min; 4°C) immediately after collection
(within 3min). Samples were also collected in serum separation
tubes and allowed to stand for 30min before centrifugation
(1300 g; 10min; 21°C). All samples were aliquoted and frozen at
−80°C until analysis.
Plasma nitric oxide analysis. Plasma samples for measurement of
total nitroso species (NOx) were aliquoted in 150-μl aliquots to
avoid freeze-thawing of the samples for each measurement.
Samples were defrosted just before the measurements took
place (within 10min) and were kept on ice throughout.
Plasma samples (n 28) were analysed for nitrite, nitrate and other
nitroso species (RXNO, including nitrosothiols, nitrosamines, iron-
nitrosylhaemoglobin and nitrosohaemoglobin) by ozone-based
chemiluminescence (model 88AM; Eco Physics) as previously
described(53). In brief, for total NOx measurement (NO derived
from nitrate, nitrite and RXNO), one aliquot of plasma was injected
into an airtight microreaction vessel containing a solution of
vanadium (III) chloride (50mM) dissolved in 1M-HCl, connected
to a chemiluminescence analyser. For measurement of nitrite
and other RXNO (i) one aliquot of plasma was injected in the
same apparatus into glacial acid acetic solution containing
45mM-potassium iodide and 10mM-iodide, at 60°C, actively
purged by inert He, which allowed the detection of NO from both
nitrite and RXNO (but no nitrate). (ii) Subsequently, the plasma
sample was treated with acidic sulphanilamide (1M-HCl) to sca-
venge nitrite, before injection, allowing for quantiﬁcation of RNXO
alone. Nitrite levels in the plasma samples were determined by the
difference between these two measurements (i and ii). Nitrate
concentration was determined by subtracting nitrite +RXNO from
total NOx. Samples used for calibration curves were prepared
fresh every day and displayed consistent values across days.
Plasma baseline lipids and glucose. Plasma levels of total
cholesterol, LDL-cholesterol, HDL-cholesterol, glucose and TAG
were assayed on an ILAB 600 chemistry analyzer (Instrumentation
Laboratory) using enzyme-based colourimetric tests supplied by
Instrumentation Laboratory.
Power calculation and statistical analysis
Power calculations were performed for the primary end point –
change in FMD response. Power was based on the intra-individual
variability of the operator who performed the FMD analysis
(5% CV, SD= 0·3%). Previous measures of variability in a control
group estimated the standard deviation within subjects to be 2·3%.
At 90% power and 0·05 signiﬁcance, the number of volunteers
required to detect a difference of 1·5% in the response of matched
pairs in a cross-over study was twenty-ﬁve. All statistical analyses
were performed using SPSS Statistics 21 (IBM) package. FMD,
blood pressure, plasma levels of nitric oxide species (nitrate, nitrite
and RNXO) and plasma levels of ﬂavanones were analysed using
a two-way repeated measures ANOVA within subjects with time
(0, 2, 5, 7h) and treatment (C, OJ, FROJ, WO) as main factors.
Post hoc and pair-wise comparisons were carried out using the
Bonferroni correction for multiple comparisons. Signiﬁcance was
deﬁned as P<0·05 (95% CI) for all outcome measures, with
P values represented in the ﬁgures as follows: *P=0·01–0·05,
**P= 0·001–0·01, ***P<0·001. Pharmacokinetic parameters were
calculated as follows: (a) the maximum plasma concentration
(Cmax) and (b) the time to reach the maximum plasma
concentration (Tmax) were determined from the individual data
obtained from each participant; (c) the area under the plasma
concentration v. time curve (AUC) was calculated using the
trapezoidal method. Multiple regression analysis was used to
predict the value of FMD (dependent variable) based on the
values of hesperetin and naringenin plasma levels (independent
variables). Random allocation sequence was generated by a third
party statistician using SAS version 9.1 (procedure plan and
seed=122700). The randomised block design contained four
blocks and nine randomised sequences within each block.
Results
Baseline characteristics and tolerance of intervention
The baseline characteristics of volunteers recruited were within the
desired ranges, with TAG ranging from 0·8 to 3·2mmol/l and total
cholesterol from 6·0 to 8·0mmol/l or/and BMI from 25 to 32kg/m2
(Table 3). All intervention beverages were well tolerated by all
volunteers, as well as the high- and medium-fat meals adminis-
tered throughout the study. No adverse events were reported.
Flavanone modulation of postprandial ﬂow-mediated
dilatation
A two-factor repeated-measures ANOVA for endothelium-
dependent brachial artery vasodilation, measured FMD response,
revealed a highly signiﬁcant interaction between the interventions
(C, OJ, FROJ, WO) and time of the day (0, 2, 5, 7h) (F9,243=3·27,
P<0·0001), as well as signiﬁcant main effects of time of the day
(F3,81=12·062, P<0·0001) and intervention (F3,81=2·78, P<0·05).
At baseline (t=0h), there were no signiﬁcant differences in
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brachial artery FMD between visits, with the average baseline levels
of FMD for the study population being 4·80 (SEM 0·03) FMD units.
After 2h of intake of the high-fat meal, a signiﬁcant decrease in %
FMD was detected for both control (P<0·0001) and the three
ﬂavanone interventions (P<0·05) (Fig. 2). In particular, in the
control group, the % FMD decreased by 0·99 (SEM 0·17)% FMD
after 2h (P<0·0001) and remained signiﬁcantly suppressed
5h (P<0·05) and 7h (P<0·0001) after intake, relative to baseline
levels. In contrast, all orange ﬂavanone interventions resulted
in a recovery in % FMD to that of baseline levels between 5 and
7h (OJ: 4·51 (SEM 0·23)% FMD; FROJ: 4·74 (SEM 0·25)%
FMD and WO: 4·75 (SEM 0·23)% FMD) (Fig. 2). At 5h post inter-
vention, there were no signiﬁcant differences in % FMD between
control and each of the ﬂavanone interventions (OJ, FROJ, WO),
whereas at 7h (following intake of the medium-fat meal at 5·5h)
we observed a signiﬁcantly higher % FMD for OJ (P<0·05),
FROJ (P<0·01) and WO (P<0·01) in comparison with
control. There were no signiﬁcant differences between the
ﬂavanone interventions at 7h, with all three doses of ﬂavanones
administered (OJ: 128·8mg; FROJ: 272·1mg and WO: 452·7mg)
counteracting the deleterious effect of the double-meal
challenge on % FMD response to a similar extent. Blood
pressure was not signiﬁcantly altered following consumption of
any of the ﬂavanone interventions, relative to baseline or to the
control beverage (Table 4).
Modulation of plasma ﬂavanones
Total ﬂavanones, naringenin and hesperetin (including
glucuronides and sulphates), were not detected in the plasma
of volunteers at baseline, indicating compliance to the
24-h low-ﬂavonoid diet before the study visits. Flavanone
metabolites were not detected in the circulation of individuals
following intake of the control drink (Fig. 3). Signiﬁcant
increases in plasma levels of hesperetin metabolites were
detected at 5 and 7 h (P< 0·0001) (Fig. 3(a)) and at 2, 5 and
7 h for naringenin metabolites (P< 0·0001) (Fig. 3(b)). The time
to reach Tmax for hesperetin and naringenin was not
signiﬁcantly different between treatments and coincided with
the timeframe of FMD effects (Table 5). At 2, 5 and 7 h, plasma
levels of naringenin were signiﬁcantly higher following WO
intake compared with OJ (P< 0·01) (Fig. 3(b)). Similarly, at
7 h, both FROJ and WO showed a trend towards higher plasma
concentrations of hesperetin, relative to OJ (P< 0·1) (Fig. 3(a)).
With respect to the Cmax and AUC (0–24 h) for plasma
hesperetin, both FROJ and WO were signiﬁcantly higher
than after OJ (P< 0·05), whereas for naringenin, both Cmax and
AUC were only signiﬁcantly higher for WO in relation to OJ
(P< 0·005) (Table 5). No signiﬁcant differences in plasma
ﬂavanone levels were detected between FROJ and WO
despite the different levels present in the treatment drinks.
At 24 h, the levels of ﬂavanones were not signiﬁcantly different
from baseline, indicating that the ﬂavanone metabolites have
been cleared from circulation (P= 0·13) (Fig. 3). A multivariate
regression analysis, including both plasma naringenin and
hesperetin, showed that hesperetin (P= 0·001), but not
naringenin (P= 0·092), predicted changes in % FMD over
the course of 0–7 h. Speciﬁcally, at 7 h, at the peak of FMD
response, hesperetin signiﬁcantly predicted the magnitude of
FMD increase (r 0·32, P= 0·005) following ﬂavanone intake.
Modulation of plasma nitrite, nitrate and nitroso species
including nitrosothiols, nitrosamines, iron-nitrosylhaemoglobin
and nitrosohaemoglobin
Levels of nitrate, nitrite and other RXNO species were deter-
mined in plasma at baseline and 2, 5 and 7 h after treatment
(Fig. 4). Nitrite plasma levels are known to reﬂect more
Table 3. Baseline clinical characteristics of the study population
(Mean values with their standard errors)
Baseline characteristics Mean SEM
Age (years) 48 1
BMI (kg/m2) 28·4 0·4
Total cholesterol (mmol/l) 5·6 0·2
HDL-cholesterol (mmol/l) 1·3 0·3
TAG (mmol/l) 1·5 0·1
Fasting glucose (mmol/l) 4·8 0·1
Hb (g/l) 149 1·0
Systolic blood pressure (mmHg) 124·0 1·7
Diastolic blood pressure (mmHg) 74·9 1·5
Liver enzymes
Alanine aminotransferase (IU/l) 42·1 2·1
γ-Glutamyltransferase (IU/l) 41·7 5·3
5.5
5.0
4.5
4.0
3.5
FM
D
 (%
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0 2 4 6 8
Time (h)
‡
‡
‡
**
*
Fig. 2. Time course of postprandial flow-mediated dilatation (FMD) following
consumption of flavanone beverages containing either 128·88mg of flavanones
(OJ, ), 272·14mg of flavanones (FROJ, ), 452·80mg of flavanones
(WO, ) or a macronutrient- and micronutrient-matched control ( ) in
middle-aged healthy men (n 28). A high-fat breakfast (51 g of fat) was
administered at t=0 h, and a medium-fat lunch (30 g of fat) was administered at
t= 5·5 h. Values are means, with their standard errors and analysed using a
two-factor repeated-measures ANOVA with time and treatment as the two
factors (significant main effects of time × treatment (P< 0·0001), time
(P< 0·0001) and treatment (P< 0·05)). Post hoc analyses were conducted
using Bonferroni’s multiple comparison test. * P< 0·05 OJ significantly different
from control at the 7 h; ** P< 0·01 FROJ and WO significantly different from
control at 7 h. ‡ Significant decrease in FMD response in relation to baseline
levels for both control (at 2, 5 and 7 h; P< 0·0001, P< 0·05, P< 0·0001,
respectively) and all three flavanone interventions (at 2 h; P< 0·05). OJ, orange
juice; FROJ, flavanone-rich orange juice; WO, whole blended orange.
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accurately endogenous NO production in humans (estimate of
70–80% of plasma nitrite deriving from eNOS activity), whereas
the other major source is diet-derived nitrate (by reduction
to nitrite). This was the rational for detecting separately levels of
nitrite, nitrate and other RXNO species. The average levels of
plasma nitrate, nitrite and other RXNO at baseline were
32·1 μmol/l, 68·3 nmol/l and 0·4 nmol/l, respectively, which is in
agreement with the values reported in the literature(37,54).
A signiﬁcant decrease in plasma nitrate levels was observed at
2, 5 and 7 h for all the interventions, including control
(P< 0·0001) (Fig. 4(b)). In contrast, plasma nitrite levels
remained constant up to 7 h after treatment (not signiﬁcantly
different from baseline) following OJ, FROJ and WO intake,
whereas the control group nitrite levels decreased signiﬁcantly
(P< 0·01) (Fig. 4(a)). No signiﬁcant changes were detected in
RXNO levels in plasma (NS) (Fig. 4(c)).
Discussion
Considerable evidence suggests that dysregulation of endothelial
function in the postprandial state is an important contributing
factor for CVD risk(2,5,7,8), whereas intakes of ﬂavonoid/
polyphenol-rich foods such as cocoa, tea and berries have been
shown to exert positive effects on vascular function. In support
of this, clinical trial data have indicated that intakes of such
foods/beverages may lower CVD disease risk, at least partially,
through their actions in mitigating fed-state metabolic and
vascular disturbances(34). In the present study, we showed
that intervention with orange ﬂavanones, both as juice and
whole orange in homogenised form, counteracts impairments in
vascular function evoked by a sequential double-meal challenge,
which reﬂects a regular eating pattern and a typical dietary intake
in the population(48). Each ﬂavanone intervention tested was
effective in reversing vascular impairments, to a physiologically
similar degree, despite them containing different levels of
ﬂavanones (ranging from 128 to 452mg) and resulting in
different concentrations of plasma ﬂavanone metabolites. No
changes in blood pressure were observed. The rescue of
transient impairments in vascular function, as assessed using
brachial artery FMD, coincided with the peak of ﬂavanone
metabolites (total sulphates and glucuronides) in circulation (7 h)
and with sustained levels of plasma nitrite, the latter of which
was signiﬁcantly reduced by the double-meal challenge. Thus,
our data support the concept that the observed postprandial
vascular beneﬁts may be linked to the actions of circulating
ﬂavanone metabolites on NO bioavailability.
Table 4. Acute postprandial effects of orange flavanone beverages on static blood pressure
Blood pressure (mmHg) Baseline 2 h 5 h 7 h P
Systolic
Control 125·5 1·9 126·7 1·9 126·7 1·7 128·6 1·5 NS
OJ 124·8 1·5 125·7 1·2 125·72 1·5 126·4 1·5
FROJ 126·1 2·1 125·7 2·0 127·3 2·1 127·1 1·6
WO 126·1 1·6 125·1 1·4 124·8 1·5 126·6 1·5
Diastolic
Control 75·6 1·6 71·5 1·4 74·6 1·4 72·1 1·4 NS
OJ 74·9 1·5 70·1 1·2 73·7 1·5 70·4 1·5
FROJ 75·5 1·5 70·9 1·6 74·6 1·5 72·2 1·4
WO 76·0 1·6 69·9 1·4 73·9 1·5 70·9 1·5
OJ, Tropicana pure premium orange juice without pulp; FROJ, flavanone-rich orange juice: Tropicana pure premium orange juice with added orange
pomace; WO, juice made from lightly blended fresh whole orange.
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Fig. 3. Plasma flavanone profile following postprandial consumption of flavanone
beverages containing either 128·88mg of flavanones (OJ, ), 272·14mg of
flavanones (FROJ, ), 452·80mg of flavanones (WO, ) or a
macronutrient- and micronutrient-matched control ( ) in middle-aged healthy
men (n 20). (a) Hesperetin, (b) naringenin. Values are means, with their standard
errors and analysed using a two-factor repeated-measures ANOVA with time and
treatment as the two factors (significant main effects of time× treatment (P<0·0001),
time (P<0·0001) and treatment (P<0·001). Post hoc analyses were conducted
using Bonferroni’s multiple comparison test. Hesperetin levels are significantly
higher in all treatments in comparison with control at 5 and 7h (‡ 0·00<P<0·02),
whereas naringenin levels are significantly higher in all treatments in comparison
with control at 2, 5 and 7h (‡ 0·00<P<0·03). Levels of plasma naringenin
are significantly higher in OJ in comparison with WO: **P<0·01, ***P<0·001.
§ Levels of plasma hesperetin in FROJ andWO show a trend towards higher values
than OJ (P<0·1). OJ, orange juice; FROJ, flavanone-rich orange juice; WO, whole
blended orange.
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Fig. 4. Plasma nitric oxide levels following postprandial consumption of
flavanone beverages containing either 128·88mg of flavanones (OJ, ),
272·14mg of flavanones (FROJ, ), 452·80mg of flavanones (WO, )
or a macronutrient- and micronutrient-matched control ( ) in middle-aged
healthy men (n 28). (a) Nitrite levels (nmol/l), (b) nitrate levels (μmol/l), (c) nitroso
species including nitrosothiols, nitrosamines, iron-nitrosylhaemoglobin and
nitrosohaemoglobin (nmol/l). Values are means, with their standard errors and
expressed as change from baseline. Data were analysed using a two-factor
repeated-measures ANOVAwith time and treatment as the two factors (significant
main effects of time (P<0·0001)). Post hoc analyses were conducted using
Bonferroni’s multiple comparison test. ** Nitrite levels are significantly different
from baseline only for the control group at the specified time points (P<0·01).
*** Nitrate levels are significantly different from baseline for both control and all
three flavanone treatments (P<0·0001) at the specified time points. OJ, orange
juice; FROJ, flavanone-rich orange juice; WO, whole blended orange.
8 C. Rendeiro et al.
http://dx.doi.org/10.1017/S0007114516004219
Downloaded from https:/www.cambridge.org/core. The University of Reading, on 10 Jan 2017 at 16:59:40, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
Our ﬁndings are consistent with previous randomised
controlled trial (RCT) data sets indicating that cocoa ﬂavanols
partially counteract the decrease in FMD following high-fat
meal loading(32). Furthermore, pure quercetin has also been
shown to ameliorate postprandial FMD following maltose
overload(33). To our knowledge, this is the ﬁrst set of data
indicating that citrus ﬂavanones are also capable of attenuating
postprandial impairments in endothelial function following
a sequential high–medium-fat double meal in individuals
displaying mild cardiometabolic risk factors. Furthermore, and
in support of our ﬁndings, previous studies conducted in the
fasted state report that chronic interventions with ﬂavanones in
at-risk groups (e.g. hypertensive, overweight or the metabolic
syndrome patients) induce positive effects on blood pressure
and endothelial function (FMD)(45,46,55) and improvements in
microvascular reactivity(45). Most importantly, in the present
study, no dose-dependent effects on brachial artery FMD were
observed, despite the interventions containing different
amounts of ﬂavanones (WO: 3·5×OJ). This may indicate that at
these intake levels a threshold plateau may be reached, similar
to what has been shown previously with other ﬂavonoid-rich
interventions(22). It also further suggests that lower doses of
ﬂavanones (approximately 130mg) can be efﬁcacious at modu-
lating postprandial endothelial function. No changes in blood
pressure were observed in the present study, which is in
agreement with previous human intervention trials reporting
modulation of blood pressure only after chronic interventions
with ﬂavonoid-rich foods, but not in an acute manner(27,31).
We observed concurrent modulation of FMD, nitrite
and circulating ﬂavanone metabolites (total sulphates and
glucuronides), suggesting that the latter may be linked to NO
availability and subsequent improvements in vascular function,
although we cannot establish a causal relationship at this time.
Speciﬁcally, both naringenin and hesperetin metabolite peak
plasma levels for all three interventions occured at approxi-
mately 7 h, which coincided with signiﬁcant improvements in
endothelial function (at 7 h) and sustained levels of circulating
nitrite after ﬂavanone interventions in comparison with control.
Plasma levels of ﬂavanone metabolites peaked slightly later
than that previously reported (4–6 h)(45,56,57), most likely due to
the concomitant intake of fat, which is thought to interfere
with ﬂavonoid absorption(58). On the other hand, no signiﬁcant
differences in time of absorption were detected between
the ﬂavanone treatment groups (peak occurs at approximately
7 h for all three treatments).
In support of the link between ﬂavanone intake and human
vascular function, we observed that when low or no levels of
ﬂavanone metabolites are detected in circulation (e.g. 2 h), no
differences in postprandial brachial FMD are observed between
control and ﬂavanone-rich beverages. Further, multiple
regression analyses suggest that mainly hesperetin metabolites
seem to predict signiﬁcantly the magnitude of changes in FMD
(r 0·32, P= 0·005), suggesting an important role of this ﬂava-
none in the effects observed. This is corroborated by previous
studies showing that pure hesperidin can trigger both acute
and chronic improvements in vascular function in humans(45,46).
It is important to further note that only the sulphated and
glucuronidated portion of the ﬂavanone metabolites were
quantiﬁed in our study, and these are likely to account for a
fraction (approximately 16%) of the total ﬂavanone metabolites
absorbed(59). As such, we anticipate that gut-derived phenolic
compounds might also contribute to the improvements in
endothelial function observed. This is supported by our
observation that hesperetin metabolites can only signiﬁcantly
predict a small percentage (approximately 30%) of the FMD
response observed; therefore, it is likely that stronger correla-
tions might be apparent once gut-derived small phenolic
metabolites are taken into consideration; however, such
extensive analysis was outside of the scope of our study.
Our study also indicates that the impairment in postprandial
FMD induced by the sequential high-fat meal might be linked to
decreases in circulating levels of NO species, particularly
nitrite and nitrate. Although the precise mechanisms underlying
postprandial endothelium impairments are not established,
mechanistic animal studies suggest a role for NO signalling,
showing, for example, that endothelial dysfunction induced
by fat intake also results in decreases in NO production(60–62).
Importantly, the ﬂavanone interventions only prevented the
decrease in nitrite, but not nitrate. Numerous evidence suggest
that nitrite reﬂects more accurately endogenous NO production in
humans, with an estimate of 70–80% of plasma nitrite deriving
from eNOS activity(63,64) and also better reﬂects the degree of
endothelial dysfunction in humans(65). In agreement with our
data, previous human clinical data suggest an ability of some
ﬂavonoid-rich foods to modulate NO bioavailability(22,24,35,37).
In particular, cocoa ﬂavanols-induced improvements in FMD
have been causally linked to NO production in humans(23). More
recently, Bondonno et al.(37), also showed that apples containing
(–) epicatechin and quercetin increased levels of nitrite along with
FMD response after 2 h of intake. In addition, and in agreement
with the present data, both pure (–) epicatechin and quercetin
were shown to speciﬁcally increase plasma nitrite, but not nitrate
in healthy humans(35). Supporting in vitro mechanistic studies
(in endothelial cells) have demonstrated that ﬂavanone
hesperetin and some of its in vivo metabolites (e.g. 7-O-β-D
glucuronide) can stimulate NO production via activation/
expression of eNOS(46,66) or by decreasing NO degradation
through inhibition of NADPH(67), and these are possible
mechanistic pathways by which ﬂavanone metabolites might
modulate postprandial FMD. Although the speciﬁc modulation
of nitrite by ﬂavanone-containing interventions is an interesting
observation in the present study, the interpretation of the temporal
dynamics (time course) of ﬂavanone appearance in plasma and
levels of plasma nitrite is not straightforward with regard to
explaining the effects of nitrite on FMD. This seems to suggest that
the impact of ﬂavanone metabolites on FMD response cannot be
explained completely by modulation of nitrite (as a measure of
NO). As the present study was not designed (or powered) to detect
changes in NO species, we are limited in our ability to establish a
clear-cut link between FMD modulation and NO at this time.
However, we believe this preliminary data are very novel and
valuable for future, more mechanism-focused, human RCT.
Interestingly, FROJ intake resulted in similar levels of plasma
ﬂavanones to WO, despite lower initial concentrations, which
might be related to characteristics of the food matrix itself, such
as viscosity, which is known to inﬂuence the bioavailability of
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polyphenols(68). It is possible that the reduced particle size of
pomace in FROJ aided the release of polyphenols from the
ﬁbre matrix, making these more accessible for gut microbiota
metabolism(69). It is known that dietary ﬁbre can physically trap
polyphenols within the ﬁbre matrix in the fruit tissue, reducing
the accessibility to enzymes and the gut microbiota(70). On the
other hand, the rate of release of polyphenols from ﬁbrous
particles is inversely proportional to the ﬁbre particle size(71);
therefore, by reducing particle size in the pomace, we are likely
to increase the bioavailability of ﬂavanones in FROJ. In order to
conﬁrm that this is the case, future studies should focus on
measuring accurately total urine excretion (e.g. over a 24 h
period). Nonetheless, our study seems to suggest that particle
size reduction of ﬁbre-rich orange pomace and the
re-introduction of this product into orange juice might be an
effective strategy to increase the bioavailability of polyphenols
in vivo. Importantly, the increased bioavailability of ﬂavanones
after FROJ intake did not enhance signiﬁcantly postprandial
FMD in comparison with lower ﬂavanone-containing OJ, again
suggesting that perhaps a certain level of ﬂavanone metabolites
is necessary in circulation to trigger postprandial FMD
improvements, but further increases in ﬂavanone levels may
not produce additional beneﬁts(22).
One of the limitations in the design of the present study is
related to the composition of the control intervention, which did
not take into account the levels of ascorbic acid present in the
citrus beverages. Clinical studies suggest that doses up to 500mg
of vitamin C do not impact on biomarkers of endothelial
function(49,72). More speciﬁcally, it has been shown in a recent
stratiﬁed meta-analysis that doses ranging from 90 to 500mg
of ascorbic acid do not produce improvements in endothelial
function, both acutely or chronically(73,74), especially in popula-
tions with normal vitamin C status(75,76). Furthermore, previous
studies reporting acute beneﬁcial effects of ascorbic acid on
endothelium-dependent vasodilation (within 2–4h of intake)
delivered doses of at least 2000mg(77–79), and in many cases
positive outcomes were achieved by delivering ascorbic acid
intravenously, resulting in supra-physiological plasma levels of
vitamin C, which cannot be achieved by oral ingestion(79,80). As
the levels of vitamin C in the present study were approximately
80–120mg, we are conﬁdent that these can be considered
negligible with respect to acute effects on endothelial function, as
measured by FMD. Therefore, despite these limitations, we can
safely argue that our conclusions are reasonable when attributing
the FMD response to circulating ﬂavanone metabolites (at 7h
post intake) and that our data are relevant in furthering the
understanding of the impact of ﬂavonoid-rich foods/beverages on
postprandial endothelial function.
In summary, our results suggest that acute intake of a
beverage containing at least 128mg of ﬂavanones can be an
effective dietary strategy to blunt the acute transient impairment
in endothelial function induced by a sequential double meal
that reﬂects a typical intake in the population. Although we
cannot draw ﬁrm conclusions regarding the mechanisms by
which ﬂavanones elicit vascular responses, our results suggest
that these might be linked to an ability of ﬂavanone metabolites
to sustain basal circulating NO levels. Collectively, these
observations have important implications, considering that most
individuals spend the majority of the day in the postprandial
state, and such temporary vascular changes repeated on a daily
basis can critically impact on long-term vascular health and
overall chronic disease risk.
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